Topics

Companies Related to "AstraZeneca licence programmes from Transg" [Most Relevant Company Matches] RSS

11:09 EDT 21st September 2019 | BioPortfolio

Here are the most relevant search results for "AstraZeneca licence programmes from Transg" found in our extensive corporate database of over 50,000 company records.

Showing "AstraZeneca licence programmes from Transg" Companies 1–25 of 234

Relevant

Custom Pharmaceuticals Limited

Established 1979 Independently owned UK MCA Manufacturing Licence EU GMP Approval UK Specials Manufacturing Licence Wholesale Dealers Home Office CD Licence Investors in People Award 120 full time staff Production Facilities on 2 sites (70,000sq ft) Sales in 2002, €14 million


AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of $32.8 billion in 2009. In the United States, AstraZe...

AstraZeneca Pharmaceuticals LP

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of $32.8 billi...


AstraZeneca and The Medicines Company

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines ar...

AstraZeneca HealthCare Foundation

Established in 1993, the AstraZeneca HealthCare Foundation is a Delaware not-for-profit corporation and a 501(c)(3) entity organized for charitable purposes including to promote public awareness of healthcare issues, to promote public education of medical knowledge and to support or contribute to charitable and qualified exempt organizations consistent wit...

AstraZeneca AS

AstraZeneca er et av verdens ledende farmasøytiske selskaper. Vi bruker hvert år ca. 25 milliarder norske kroner på forskning verden over for å utvikle nye medisiner. Dette har resultert i en rekke nyskapende og effektive legemidler. AstraZeneca har som forretningside å utvikle og markedsføre kostnadseffektive behandlingsløsninger basert på innovative legemidler for å fremme helse og livs...

Ironwood Pharmaceuticals, Inc. and AstraZeneca Pharmaceuticals Co., Ltd.

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its i...

AstraZeneca and Bristol-Myers Squibb

Dedicated to addressing the global burden of diabetes by advancing individualized patient care, AstraZeneca and Bristol-Myers Squibb are working in collaboration to research, develop and commercialize a versatile portfolio of innovative treatment options for diabetes and related metabolic disorders that aim to provide treatment effects beyond glucose contr...

AstraZeneca and Bristol-Myers Squibb Company

Dedicated to addressing the global burden of diabetes by advancing individualized patient care, AstraZeneca and Bristol-Myers Squibb are working in collaboration to develop and commercialize a versatile portfolio of innovative treatment options for diabetes and related metabolic disorders that aim to provide treatment effects beyond glucose control. Find o...

Bristol-Myers Squibb Company & AstraZeneca

Bristol-Myers Squibb and AstraZeneca entered into a collaboration in January 2007 to enable the companies to research, develop and commercialize select investigational drugs for type 2 diabetes. The Bristol-Myers Squibb/AstraZeneca Diabetes collaboration is dedicated to global patient care, improving patient outcomes and creating a new vision for the treat...

Bristol-Myers Squibb Company and AstraZeneca

Bristol-Myers Squibb and AstraZeneca entered into a collaboration in January 2007 to enable the companies to research, develop and commercialize select investigational drugs for type 2 diabetes. The Bristol-Myers Squibb/AstraZeneca Diabetes collaboration is dedicated to global patient care, improving patient outcomes and creating a new vision for the treat...

Bristol-Myers Squibb and AstraZeneca

Bristol-Myers Squibb and AstraZeneca entered into a collaboration in January 2007 to enable the companies to research, develop and commercialize select investigational drugs for type 2 diabetes. The Bristol-Myers Squibb/AstraZeneca Diabetes collaboration is dedicated to global patient care, improving patient outcomes and creating a new vision for the treat...

TikoMed

Swedish-based TikoMed is an innovation driven biotechnology company focused on the development and commercialization of novel treatments for transplantation therapies and immune diseases. The board includes Anders Milton, former chairman of Swedish Red-Cross and Q-Med, Jan Sandström, previously Vice President Business Development at AstraZeneca and Gillis ...

Bristol-Myers Squibb Company

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

BTG Plc

BTG in-licenses, develops and commercialises pharmaceuticals, targeting neurological and other disorders. The company has a substantial and growing revenue stream of royalties from out-licensed products, a broad internal pipeline of development programmes and a pipeline of licensed programmes. Listed on the London Stock Exchange since 1995 (LSE: BGC), the company employs around 70 people in Lond...

Albireo AB

Albireo is an independent Swedish biotechnology company, which brings unique translational approaches to develop drugs that fulfill unmet medical needs in the gastrointestinal (GI) area. The Albireo team has a broad experience in drug development, primarily in the GI area and has an extensive network in the international scientific and clinical communities. Albireo was created as a spin out of...

AstraZeneca Plc

AstraZeneca AstraZeneca

Pharma Marketing Academy

Pharma Marketing Academy is an independent company providing marketing development programmes to the Pharmaceutical Industry designing and carrying out full company "Marketing Health Checks" - involving interviews exploring competencies, analysing the marketing and sales processes and cross-functional team effectiveness - in order to provide strategic recommendationsdesigning, developing and del...

Incyte Corporation and AstraZeneca

Cigna Corporation and AstraZeneca

NorDiag ASA

We at NorDiag have developed a novel, proprietary DNA-based technology for cancer testing. We believe our technology will help increase patient participation in cancer screening programmes and hasten the successful launch of new screening programmes. Key benefits to our product Genefec™ are its non-invasiveness, scalability, cost-effectiveness and its accuracy at the early stages of cancer devel...

AstraZeneca and The University of Texas MD Anderson Cancer Center

Amura Therapeutics Ltd

Amura has two complementary technology platforms which enable rapid and innovative drug discovery. AMcore™, the bicyclic core molecular scaffold chemistry and the computational screening and design platform, ProtoDiscovery™. Amura has four NCE discovery programmes based on AMcore™: An Osteoporosis programme based on cathepsin K inhibitors A Psoriasis programme based on a cathepsin S inhibit...

Probably Relevant

ITI Life Sciences

ITI Life Sciences drives the sustainable growth of the life sciences sector in Scotland, through successful and creative deployment of its £150 million innovation fund.Publicly funded, but 100% commercially driven, we fund and manage early stage technology research and development programmes in the life sciences arena. We select and invest in programmes based on assessing future market needs, ide...


More From BioPortfolio on "AstraZeneca licence programmes from Transg"

Quick Search

Corporate Database Quicklinks